HBV RNA profiles in chronic hepatitis B patients under different disease phases and anti-viral therapy

Hepatitis

Pre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy

Hepatology.

Carey I, Gersch J, Wang B, Moigboi C, Kuhns M, Cloherty G, Dusheiko G, Agarwal K

doi: 10.1002/hep.31026.

Hepatitis

Indication for treatment and severity of disease in treatment-naive patients with chronic hepatitis B virus infection

Eur J Gastroenterol Hepatol.

Post G, Shalev N, Baumgarten A, Shimakawa Y, Lemoine M, Krznaric I, Dupke S, Carganico A, Arastéh K, Ingiliz P

doi: 10.1097/MEG.

Hepatitis

RNA Interference Therapy with ARC-520 Results in Prolonged HBsAg Response in Patients with Chronic Hepatitis B Infection

Hepatology.

Yuen MF, Schiefke I, Yoon JH, Ahn SH, Heo J, Kim JH, Chan HLY, Yoon KT, Klinker H, Manns M, Petersen J, Schluep T, Hamilton J, Given BD, Ferrari C, Lai CL, Locarnini SA, Gish RG

doi: 10.1002/hep.31008.

Hepatitis

Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials

Lancet Gastroenterol Hepatol.

Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos , Crans G, Flaherty J, Gaggar A, Marcellin P

doi: 10.1016/S2468-

Gastrointestinal CancerHepatitisHepatology

High Level of Hepatitis B Core-related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load

Gastroenterology.

Tseng TC, Liu CJ, Hsu CY, Hong CM, Su TH, Yang WT, Chen CL, Yang HC, Huang YT, Fang-Tzu Kuo S, Liu CH, Chen PJ, Chen DS, Kao JH

doi: 10.1053/j.gastro.2019.08.028.

Hepatitis

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study

Lancet Gastroenterol Hepatol.

Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, Ramji A, Chen CY, Tam E, Bae H, Ma X, Flaherty JF, Gaggar A, Lau A, Liu Y, Wu G, Suri V, Tan SK, Subramanian GM, Trinh H, Yoon SK, Agarwal K, Lim YS, Chan HLY

doi: 10.1016/S2468-1253(19)30421-2.

HepatitisHepatology

Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients

J Gastroenterol Hepatol

Kaneko S, Kurosaki M, Inada K, Kirino S, Hayakawa Y, Yamashita K, Osawa L, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Izumi N

doi: 10.1111/jgh.15563

Hepatitis

Use of Hepatitis B Virus Core Related Antigen to Evaluate Natural History of Chronic Hepatitis B

J Gastroenterol Hepatol.

Chan HLY, Yasuda S, Wong GLH, Tada T, Chan CKM, Kumada T, Tse YK, Wong VWS, Toyoda H

doi: 10.1111/jgh.15058.

Further Publications

Hepatic decompensation in cirrhotic patients receiving antiviral therapy for chronic hepatitis B

Clin Gastroenterol Hepatol

Lee HW, Cheuk-Fung Yip T, Tse YK, Lai-Hung Wong G, Kim BK, Kim SU, Park JY, Kim DY, Lik-Yuen Chan H, Ahn SH, Wai-Sun Wong V

doi: 10.1016/j.cgh.2020.08.064

Related content

Pre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy

Indication for treatment and severity of disease in treatment-naive patients with chronic hepatitis B virus infection

RNA Interference Therapy with ARC-520 Results in Prolonged HBsAg Response in Patients with Chronic Hepatitis B Infection

Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials

High Level of Hepatitis B Core-related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study

Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients

Use of Hepatitis B Virus Core Related Antigen to Evaluate Natural History of Chronic Hepatitis B

Hepatic decompensation in cirrhotic patients receiving antiviral therapy for chronic hepatitis B